A syringe with the coronavirus vaccine AstraZeneca. The Oxford trial involves 200 young people between the ages of 6 and 17, and has been going on since mid-February, according to the WSJ. However, regulatory bodies are continuing to review the vaccine—which has not yet been approved for emergency use in the U.S.—following reports of rare blood clots in multiple countries. The British government announced last week that it had seen 30 severe blood clotting cases reported out of 15.8 million administered doses of the AstraZeneca vaccine, seven of whom died. Further Reading“Scientists Say They Found Cause of Rare Blood Clotting Linked to AstraZeneca Vaccine” (Wall Street Journal)“AstraZeneca Covid-19 Vaccine Has ‘Clear’ Link To Rare Blood Clots, European Public Health Official Says” (Forbes)Full coverage and live updates on the Coronavirus

Source: Forbes April 06, 2021 18:32 UTC